

REMARKS

The Specification and Claims have been amended to include sequence identification numbers which were omitted at the time of filing.

Attached hereto is a marked-up version of the changes made to the Specification and Claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

The undersigned hereby states that the computer readable form copy (CRF copy) of the Sequence Listing and the paper copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 406462000210. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: November 7, 2001

By: Karen Babyak Dow
Karen Babyak Dow
Registration No. (29,684)

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7960
Facsimile: (858) 720-5125

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at page 8, line 4, has been amended as follows:

The endogenous hydrophobic sequence or the exogenous hydrophobic sequence is an amino acid sequence is preferably between about 5 and about 29 residues. Preferred short exogenous hydrophobic sequences are Phe-Leu-Leu-Ala-Val (SEQ ID NO:2) or Val-Ala-Leu-Leu-Phe (SEQ ID NO:3). The exogenous hydrophobic material may also be C8-C18 fatty acyl group, preferably lauroyl.

Paragraph beginning at page 26, line 3, has been amended as follows:

The results of several tests of the production and use of the present vaccine composition are detailed in TABLES 2-4. All vaccines were prepared as described below. Briefly, the peptides, with or without added cysteines, were synthesized by standard solid phase technology. While still on the resin, a lauroyl group was added to the amino terminus as described below or the pentapeptide hydrophobic foot, Phe-Leu-Leu-Ala-Val (FLLAV) (SEQ ID NO:2), was added by simply continuing the synthesis. Except when noted otherwise, all vaccines were prepared by dissolving the peptides and/or the proteosomes in TEEN-1% detergent buffer and then exhaustively dialyzing away the detergent.

Paragraph beginning at page 31, line 9, has been amended as follows:

The synthetic DNA hydrophobic decapeptide anchor sequence (1 µg) identified below was then added and ligated to the SmaI/SalI cut pR32 (100ng) in 30 µl ligase buffer with one unit of T4-DNA ligase at 4C for 16 hours. The hydrophobic decapeptide coding sequence was:

5'GGT GGT TAC TGC TTC GTT GCT CTG CTG TTC TGA G (SEQ ID NO:17)

3'CCA CCA ATG ACG AAG CAA CGA GAC GAC AAG ACT CAGCT (SEQ ID NO:18).

In the Claims:

Please amend claim 5 as follows:

5. (Amended) A vaccine composition according to claim 1 wherein the exogenous hydrophobic material is Phe Leu Leu Ala Val (SEQ ID NO:2) or Val Ala Leu Leu Phe (SEQ ID NO:3).